Key result
Targeted PAH therapy is linked to an absolute ~0.6-grade reduction in tricuspid regurgitation severity.
Why the study?
While tricuspid regurgitation (TR) is frequent in patients with pulmonary arterial hypertension (PAH), the impact of guideline-directed targeted PAH therapy on TR severity and echocardiographic right heart parameters had not been thoroughly studied.
Does targeted PAH therapy (upfront dual oral PDE5i/ERA or add-on sotatercept) reduce functional tricuspid regurgitation severity and improve right heart remodeling in patients with pulmonary arterial hypertension?
Observational (n=114)
Does targeted PAH therapy (upfront dual oral PDE5i/ERA or add-on sotatercept) reduce functional tricuspid regurgitation severity and improve right heart remodeling in patients with pulmonary arterial hypertension?
Targeted medical therapy for pulmonary arterial hypertension, whether upfront dual oral therapy (PDE5i and ERA) or add-on sotatercept, significantly improves invasive hemodynamics and substantially reduces functional tricuspid regurgitation severity and right heart remodeling.
Answers are grounded in this paper and cite their sources.
Supports PAH therapy for secondary TR; extends remodeling evidence to tricuspid outcomes in Level 1 data.
Background Tricuspid regurgitation (TR) is a common condition, and severe TR is associated with worsening heart failure and impaired survival. Aetiology is secondary in >90% of cases, and associated with pressure and/or volume load. While TR is frequent in patients with pulmonary arterial hypertension (PAH), the impact of guideline-directed targeted PAH therapy on TR severity and echocardiographic right heart parameters has not thoroughly been studied. Methods We analyzed the impact of PAH therapies on the degree of TR in two scenarios: Group A comprised 88 patients with incident PAH, in whom upfront dual oral PAH combination therapy with a phosphodiesterase-5 inhibitor (PDE5i) and an endothelin receptor antagonist (ERA) was initiated; Group B consisted of 26 patients with prevalent PAH on stable background therapy who received the novel activin signaling inhibitor sotatercept as add-on therapy. All patients underwent structured follow-up, including repeat right heart catheterization (RHC) and echocardiography. TR severity was quantified as overall grading (0=none/trace, 1=mild, 2=moderate, 3=severe), vena contracta [VC], and tricuspid valve [TV] annulus. Results Patients´ mean age was 56.8±17.6 years, 65.8% were female, and 34.9/60.4% were in WHO-FC II/III, respectively. In group A, all patients were initiated on combination therapy (PDE5i and ERA), which led to improvements of mean pulmonary artery pressure (mPAP; 49.76±13.51 to 38.07±10.92 mmHg), pulmonary vascular resistance (PVR; 10.85±5.39 to 5.17±2.73 WU), and pulmonary artery compliance (PAC; 1.08±0.61 to 2.12±1.01 ml/mmHg) (all p<0.05). Concomitant reverse right heart remodeling was associated with reductions in TR grade (1.72±0.87 to 1.14±0.79), VC width (4.45±2.71 to 2.79±1.97 mm), and TV annulus (36.30±6.02 to 32.92±5.48 mm) (all p<0.05). In group B, add-on sotatercept to existing background therapy led to further improvements of mPAP (53.69±13.42 to 41.55±13.87 mmHg), PVR (11.08±5.03 to 7.49±4.25 WU), and PAC (1.19±0.60 to 1.96±0.98 ml/mmHg) (all p<0.05). Add-on Sotatercept was associated with reductions in TR severity (grade 2.12±0.82 to 1.00±0.94), VC (5.16±2.69 to 2.10±2.08 mm), and TV annulus (39.41±6.02 to 33.63±7.25 mm) (all p<0.05). Conclusions Data indicate that PAH may represent an underlying cause of functional TR, and improvement of hemodynamics by initiation of targeted medical therapy leads to substantial reduction of TR severity, along with improvements of right heart dimensions, RV function, RV–PA coupling, and clinical measures. In view of the increasing interventional treatment options for high-grade TR, these findings emphasize the importance of a comprehensive diagnostic work-up including invasive hemodynamic evaluation prior to interventional therapy, and medical therapy may be indicated in selected cases with PAH.
No takes yet. Share an insight, caveat, or question.
Gentz et al. (2026) conducted an observational in Pulmonary arterial hypertension with functional tricuspid regurgitation (n=114). Targeted PAH therapy (upfront PDE5i + ERA or add-on sotatercept) vs. Baseline (pre-treatment) was evaluated on Tricuspid regurgitation severity (overall grading 0-3) (p=<0.05). Targeted PAH therapy with PDE5i/ERA or add-on sotatercept reduced tricuspid regurgitation grade from 1.72 to 1.14 and 2.12 to 1.00, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: